Literature DB >> 12745012

Synthesis of 2'-deoxy-2'-[18F]fluoro-beta-D-arabinofuranosyl nucleosides, [18F]FAU, [18F]FMAU, [18F]FBAU and [18F]FIAU, as potential PET agents for imaging cellular proliferation. Synthesis of [18F]labelled FAU, FMAU, FBAU, FIAU.

Thomas J Mangner1, Raymond W Klecker, Lawrence Anderson, Anthony F Shields.   

Abstract

An efficient and reliable synthesis of 2'-deoxy-2'-[(18)F]fluoro-beta-D-arabinofuranosyl nucleosides is presented. Overall decay-corrected radiochemical yields of 35-45% of 4 analogs, FAU, FMAU, FBAU and FIAU are routinely obtained in >98% radiochemical purity and with specific activities of greater than 3 Ci/micromol (110 MBq/micromol) in a synthesis time of approximately 3 hours. When approximately 220 mCi (8.15 GBq) of starting [(18)F]fluoride is used, 25 -30 mCi (0.93 -1.11 GBq) of product (enough to image two patients sequentially) is typically obtained.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12745012     DOI： 10.1016/s0969-8051(02)00445-6

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN： 0969-8051            Impact factor:   2.408


  33 in total

1.  Structure-guided engineering of human thymidine kinase 2 as a positron emission tomography reporter gene for enhanced phosphorylation of non-natural thymidine analog reporter probe.

Authors:  Dean O Campbell; Shahriar S Yaghoubi; Ying Su; Jason T Lee; Martin S Auerbach; Harvey Herschman; Nagichettiar Satyamurthy; Johannes Czernin; Arnon Lavie; Caius G Radu
Journal:  J Biol Chem       Date:  2011-11-09       Impact factor: 5.157

2.  Improved synthesis of 2'-deoxy-2'-[18F]-fluoro-1-beta-D-arabinofuranosyl-5-iodouracil ([18F]-FIAU).

Authors:  Harry Anderson; Nagavarakishore Pillarsetty; Melchor Cantorias; Jason S Lewis
Journal:  Nucl Med Biol       Date:  2010-03-06       Impact factor: 2.408

3.  Imaging chemically modified adenovirus for targeting tumors expressing integrin alphavbeta3 in living mice with mutant herpes simplex virus type 1 thymidine kinase PET reporter gene.

Authors:  Zhengming Xiong; Zhen Cheng; Xianzhong Zhang; Manish Patel; Joseph C Wu; Sanjiv S Gambhir; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2006-01       Impact factor: 10.057

Review 4.  [18F]FLT-PET in oncology: current status and opportunities.

Authors:  Lukas B Been; Albert J H Suurmeijer; David C P Cobben; Pieter L Jager; Harald J Hoekstra; Philip H Elsinga
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-12       Impact factor: 9.236

Review 5.  Molecular imaging of prostate cancer: PET radiotracers.

Authors:  Hossein Jadvar
Journal:  AJR Am J Roentgenol       Date:  2012-08       Impact factor: 3.959

Review 6.  Imaging in targeted delivery of therapy to cancer.

Authors:  Gairin Dancey; Richard H Begent; Tim Meyer
Journal:  Target Oncol       Date:  2009-10-08       Impact factor: 4.493

7.  5-[18F]Fluoroalkyl pyrimidine nucleosides: probes for positron emission tomography imaging of herpes simplex virus type 1 thymidine kinase gene expression.

Authors:  Ann-Marie Chacko; Eric Blankemeyer; Brian P Lieberman; Wenchao Qu; Hank F Kung
Journal:  Nucl Med Biol       Date:  2009-01       Impact factor: 2.408

8.  Semiautomated radiosynthesis and biological evaluation of [18F]FEAU: a novel PET imaging agent for HSV1-tk/sr39tk reporter gene expression.

Authors:  Frederick T Chin; Mohammed Namavari; Jelena Levi; Murugesan Subbarayan; Pritha Ray; Xiaoyuan Chen; Sanjiv S Gambhir
Journal:  Mol Imaging Biol       Date:  2007-12-22       Impact factor: 3.488

Review 9.  Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology.

Authors:  Anthony F Shields
Journal:  Mol Imaging Biol       Date:  2006 May-Jun       Impact factor: 3.488

10.  Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [18F]-labeled 2'-deoxycytidine analog.

Authors:  Caius G Radu; Chengyi J Shu; Evan Nair-Gill; Stephanie M Shelly; Jorge R Barrio; Nagichettiar Satyamurthy; Michael E Phelps; Owen N Witte
Journal:  Nat Med       Date:  2008-06-08       Impact factor: 53.440
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.